Antengene is a leading clinical-stage R&D driven biopharmaceutical company focused on innovative medicines for oncology and other life-threatening diseases. Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world.We distinguish ourselves through our industry-leading R&D capabilities and differentiated strategic approach to developing novel oncology therapies. Our vision is to treat patients beyond borders and transform their lives by discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies. Antengene was listed on the Main Board of The Stock Exchange on 20th December 2020, SEHK: 6996.HK.
By efficiently utilizing our resources and leveraging our outstanding capability in target selection and differentiated discovery and development strategy, we have established a robust and highly innovative pipeline of 13 drug assets focused on oncology and other indications, including two late-stage clinical assets and four early-stage clinical assets, and we have submitted 5 new drug applications (NDA) in multiple markets in Asia Pacific. In addition, leveraging our strong R&D capabilities, we are internally developing six pre-clinical stage assets, which focus on novel targets or MoAs and hence have first-in-class potential to address significant unmet medical needs. More importantly, these assets target the key oncogenic pathways and are highly synergistic to our pipeline assets.
Since establishment, we have built a solid research & development infrastructure and clinical development capabilities across the Asia Pacific (APAC). We are expanding our own commercial teams in APAC in anticipation of near term launches in multiple countries and regions. Our commercial teams are composed of leaders from MNCs with rich global and regional commercialization experience as well as local field force who have in-depth understanding of dynamics of each market.